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The HIV viral entry co-receptors CCR5 and CXCR4 function physiologically as 
typical chemokine receptors. Activation leads to cytosolic signal transduction that 
results in a variety of cellular responses such as cytoskeletal rearrangement and 
chemotaxis (CTX). Our aim was to investigate the signalling pathways involved in 
CC-and CXC-receptor mediated cell migration. Inhibition of dynamin I and II GTPase 
with dynasore completely inhibited CCL3 stimulated chemotaxis in THP-1 cells, 
whereas the dynasore analogue dyngo-4a, which is a more potent inhibitor, showed 
reduced ability to inhibit CC-chemokine induced CTX. In contrast, dynasore was not 
able to block cell migration via CXCR4. The same activation/inhibition pattern was 
verified in activated-T-lymphocytes for different CC-and CXC-chemokines. Cell 
migration induced by CC- and CXC-receptors is not relying on active internalisation 
processes driven by dynamin since the blockade of internalisation does not affect 
migration, but they might rely on dynamin interaction with the cytoskeleton. We 
identify here a functional difference in how CC- and CXC-receptor migration is 
controlled, suggesting that specific signalling networks are being employed for 
different receptor classes and potentially specific therapeutic targets to prevent 
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Cellular migration can be activated by chemokine receptors, which are part of the G 
protein coupled receptors family (GPCRs) [1]. In different disease settings and 
different cancer types it has been shown that chemokine receptors play a crucial role 
in promoting cell migration and even cancer growth [2, 3]. Several chemokines 
(CCL5, CCL8) act as agonists for CCR1, CCR3 and CCR5, whereas a few 
chemokines, like CCL2, only activate CCR2 and CCR4, but not CCR5 [4, 5]. It has 
been shown that chemokine receptor activation leads to activation of heterotrimeric 
G proteins and phosphorylation of the receptor via G protein coupled receptor 
kinases (GRKs), which in turn leads to binding of β-arrestins to the receptor and is 
followed by receptor internalisation [4]. Activation is also followed by actin 
polymerisation but the signalling networks become which activated to allow this to 
happen have yet to be fully defined.  
In recent years it has become clear that GPCRs do not signal solely via G proteins 
[6]. The so called receptosome of these receptors, which includes β-arrestins and 
other associating proteins makes signalling of GPCRs comparatively complex. β-
arrestins can associate directly with a range of proteins including ERK1/2, cofilin, 
filamin and Jnk3 and therefore activate a variety of cellular responses without the 
involvement of G proteins [7]. Ligand biased signalling is important for chemokine 
receptors and it allows different ligands to activate different signalling cascades by 
encouraging specific ligand-receptor conformations. Receptors adopting such ligand 
dependent conformations then display specificity or bias towards certain signalling 
pathways dependent on which ligand is binding to the receptor [8] and which 
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receptor class is involved. There is also a marked difference in the regulation of 
CXC-receptors and CC-receptors expression on the cell surfaces. Whereas CCR5, 
CCR2 and CCR4 internalise via clathrin-coated-pits and caveolae, CXCR3 and 
CXCR4 only use clathrin-coated pits [9-13]. Similarly, CCR5 recycles back to the cell 
surface, whereas CXCR3 and CXCR4 are targeted to the late endosomes and 
lysosomes [10, 12, 13].  
Traditionally it is thought that βγ-subunits of the G proteins induce migration via 
activation of PI3K [14], however we have recently shown that this seems not to be 
the case for CCL3 induced migration in THP-1 cells [15]. For CXCR4 it has been 
shown that migration under certain circumstances is dependent on β-arrestins as 
well as filamin-A, a protein, which can bind actin and interacts with β-arrestins [16, 
17]. This raises the possibility that β-arrestin and actin interacting proteins are 
activated downstream of different types of chemokine receptors. One of these actin 
interacting proteins is dynamin. Several groups have shown that dynamin, an 
enzyme which has traditionally been linked to internalisation of receptors via clathrin-
coated pits, is important for the integral structure of actin polymers [18-20]. 
Dynamins are large multi-domain proteins (∼100 kDa) that constitute an N-terminal 
GTPase domain, a middle domain, a PH domain, a GTPase effector domain (GED), 
and a C-terminal proline-rich domain (PRD), which interacts with proteins that 
contain SH3 domains [21] and there are several types of the protein: dynamin I is 
primarily found in neurones where it is involved in synaptic vesicle endocytosis [22, 
23] and it has been linked with several neurological processes such as long-term 
memory formation [24]. Dynamin II is ubiquitously expressed and is found in all cell 
types, dynamin III is primarily found in the testis. Dynamin II interacts with numerous 
GPCRs as well as non-GPCR receptors, including the chemokine receptor CCR5 [25] 
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and various cytokine receptors [26] and is, therefore, an interesting target protein to 
investigate chemokine receptor triggered migration.  
Here we analysed different small molecule inhibitors for their effects on chemokine 
receptor-induced migration and release of intracellular calcium. We investigated 
whether dynamin plays a role for both CC-receptor- as well as CXC-receptor-
induced migration or whether distinct signalling pathways are activated by different 




Cells and materials 
Culture conditions for THP-1 cells have previously been described [9]. Jurkat cells 
were obtained from ATCC and grown in RPMI containing 10% FCS and 2 mM L-
glutamine. Blood was sampled from healthy normal subjects according to a protocol 
approved by a local ethics committee (reference number 2008042). Peripheral blood 
mononuclear cells (PBMCs) were subsequently isolated as previously described by 
Sabroe et al. [27]. Lymphocytes were separated from monocytes by allowing the 
latter to adhere to a tissue culture flask for 2 hours at 37 °C and 5% CO2 and were 
activated by culture in the presence of IL-2 (200 mg/mL) and concanavalin A (30 
mg/mL) for at least 10 days. The chemokine used for CCR5/CCR1 activation was 
human CCL3 (D26A) and has been described before [9, 28]. CXCL11 and CXCL12 
were from Peprotech (UK). Dynamin inhibitors dynasore, dyngo-4a, MiTMAB, 
OcTMAB, dynole-34-2, dynole-31-2 (negative control), iminodyn-22 and iminodyn-17 
(negative control), pyrimidin-7 were purchased from Abcam (for an overview of 
dynamin inhibitors see Table 1). Clathrin-mediated endocytosis inhibitor pitstop 2 
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and the corresponding negative control were from Abcam. All other chemicals were 
from Fisher Scientific. 
 
Chemotaxis Assays 
Cells were harvested and washed twice with pre-warmed, sterile PBS, then 
resuspended in serum-free RPMI 1640 which contained 0.1% BSA. The 
concentration of cells was adjusted to 6.25 x 107 cells/mL. Chemoattractants were 
loaded in a final volume of 31 µL at indicated concentrations in the lower 
compartment and 20 µL of resuspended cells were loaded onto the upper 
compartment of a microchemotaxis chamber (Receptor Technologies, Adderbury, 
UK). The two compartments were separated by a polyvinylpyrollidone-free 
polycarbonate filter with 5 µm pores. For inhibitor treatment, cells were incubated for 
30 minutes with the inhibitor or with vehicle control before loading onto the upper 
compartment of the chamber. Chambers were incubated at 37°C and 5% CO2 for 4 
hours before cells were counted. Data was analysed as previously described [15]. 
 
Analysis of data 
Data were analysed using GraphPad Prism 5 (GraphPad Software). Statistical 
analyses were performed using a one-way ANOVA with a Bonferroni multiple 
comparison test as post-hoc test with a p value <0.05 deemed significant. In all 
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Chemokine receptors are expressed on different cell types, and THP-1 cells express 
naturally CCR1, CCR2 and CCR5 as well as CXCR4 and migrate towards stimuli 
with CCL2, CCL3, CCL8, CCL23 and CXCL12 whereas Jurkat cells express CXCR4 
and migrate towards stimuli with CXCL12, but not towards CCL3. Activated T-cells 
have been shown to express functional CXCR3 and CCR5 and migrate towards 
CXCL11 and CCL3 [29]. We therefore used these different cells to investigate the 
effect of dynamin inhibitors on cell migration with the view to differentiate between 
CC-receptor and CXC-receptor family behaviour. In our hand Jurkat cells do not 
migrate towards CCL3 and hence we used THP-1 cells for both CCL3 and CXCL12. 
Dynasore blocks migration towards CCL3 in THP-1 cells in a dose dependant 
manner (Figure 1a). At a concentration where dynasore clearly blocks CCL3 induced 
migration (40 µM), it does not affect CXCL12 induced migration in THP-1 (Figure 1b). 
To rule out any ambiguities, we used the higher concentration of dynasore (80 µM) in 
activated T-cells. Dynasore does not block migration of activated T-cells towards 
CXCL11, whereas, there is a clear trend of inhibition towards CCL3 induced 
migration (Figure 1 c,d), showing a distinct difference in the activation pattern of 
CXC- and CC-receptors. Confirming the differences between CC- and CXC-
receptors are results with CXCL12 in Jurkat cells, where dynasore has no effect at 
all on migration, even at 80 µM (Figure 1 e). At the concentration used, none of the 
dynamin inhibitors showed any cytotoxic effects in the experimental set up, as shown 
by MTS assays (data not shown). 
 
The dynasore analogue dyngo-4a, which is more potent than dynasore (dyngo-4a 
IC50 16±1.2 µM versus dynasore 79.3±1.3 µM [30]) blocks migration towards CCL3 
in THP-1 cells to a lesser degree than dynasore. Remarkably dyngo-4a blocks 
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migration towards CXCL11 in activated T-cells and CXCL12 in THP-1 and Jurkat 
cells (Figure 2). Dyngo-4a shows selectivity towards dynamin I versus dynamin II 
whereas dynasore is non-selective and therefore these results might reflect a 
different usage of the dynamin isoforms by different receptors (see Table 1). We 
further investigated which domains of the dynamin proteins are essential for cell 
migration and whether they are equally important for different receptor families. In 
the first instance, we used iminodyn-22 and dynole-34-2 which are both non-
selective dynamin I and II inhibitors, and their negative controls which are iminodyn-
17 and dynole-31-2. Neither iminodyn-22 nor dynole-34-2 block migration in THP-1 
cells towards CCL3 or in Jurkat cells towards CXCL12 (Figure 3 a-d). However there 
is a distinct difference between CCL3- and CXCL12-induced chemotaxis for the non-
selective MiTMAB and OcTMAB inhibitors which bind to the dynamin PH domain [30], 
and completely block any migration in Jurkat cells towards CXCL12 (Figure 3 f), but 
have no significant effect on CCL3-induced migration in THP-1 cells (Figure 3 e,g) 
but still effect CXCL12 migration in THP-1, even though with less of an effect than in 
Jurkat cells (Figure 3 h). Again this data shows a clear difference in the reliance of 
CC- and CXC-receptors on dynamin usage. We also used pyrimidyn-7, which 
competitively inhibits both GTP and phospholipid binding and is the only inhibitor 
available up to now which targets two distinct domains of dynamin. There is no effect 
on CCL3 induced migration in THP-1 cells (Figure 4 a), but CXCL12 induced 
migration is significantly blocked in Jurkat cells (Figure 3 b) as well as THP-1 cells 
(data not shown). 
Dynamin is classically known as being of importance for clathrin-coated pit triggered 
internalisation of receptors, even though recently its importance for actin-dynamics 
have become more apparent [19]. We previously showed that CCR5 can use 
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clathrin-coated pits for internalisation [9, 31] and indeed dynamin inhibition via 
dynasore completely abrogates internalisation on CHO.CCR5 as well as THP-1 cells 
as analysed via immunofluorescence (data not shown). To investigate whether it is 
the prohibition of internalisation which prevents cell migration, we used another 
clathrin-coated pit endocytosis inhibitor, pitstop 2 and its negative control analogue in 
THP-1 cells for CCL3 activation as well as in Jurkat cells for CXCL12 activation. 
Pitstop 2 does not block cell migration (Figure 4 c,d). The concentration of pitstop 2 
used for migration assays actually inhibits internalisation of CCR5 receptor in THP-1 
cells (data not shown). An increase of the concentration of pitstop 2 used in THP-1 





In this study we investigated the role of dynamin in the signalling events that occur 
after the activation of CC- and CXC-receptors. Dynamin involvement in cell migration 
is related to its role as a focal adhesion regulator and it has been shown that 
inhibition of dynamin 2 inhibits focal adhesion disassembly and impairs cell migration. 
We, therefore, used different dynamin inhibitors, which either have a higher potency 
for dynamin I over II (dyngo-4a) or are non-selective dynamin I and II inhibitors 
(dynasore, dynole-34-2, MiTMAB, OcTMAB, iminodyn-22, pyrimidyn-7) [30, 32, 33]. 
Dynasore has been shown previously to block endocytosis via clathrin-coated pits 
[34-36] and indeed it blocks CCL3-induced endocytosis of CCR5 in CHO.CCR5 cells. 
Dynasore blocks CCL3 induced migration in THP-1 cells and activated T-
lymphocytes, but it has no effect on either CXCL12-induced migration of THP-1 or 
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Jurkat cells or CXCL11-induced migration of activated T-lymphocytes. These results 
point towards a significant difference between CC- and CXC-receptor activated 
signalling networks. Dyngo-4a, a close analogue of dynasore, which is more potent 
than dynasore and has a higher potency for dynamin I over dynamin II [30], is less 
effective in blocking CCL3-induced migration in THP-1 cells, however it blocks 
CXCL11- and CXCL12-induced migration in activated T-lymphocytes and Jurkat 
cells, respectively. Similarly, dynasore can significantly reduce CCL2 induced 
migration in THP-1 cells, whereas dyngo-4a shows a trend to inhibit migration, but 
does not reach significance. The functional differences between dynasore and 
dyngo-4a have not been fully analysed yet, but with the knowledge available today, 
our data points towards either a different usage of dynamin isoforms by chemokine 
receptor subtypes or to the usage of a varying set of dynamin interacting protein by 
different receptor subfamilies. This difference between CC- and CXC-receptors was 
further highlighted by the use of dynole-34-2, MiTMAB, OcTMAB, iminodyn-22 and 
pyrimidyn-7. None of those blocked CCL3-induced migration in THP-1 cells, but 
pyrimidyn-7, MiTMAB and OcTMAB block CXCL12-induced migration in THP-1 and 
Jurkat cells. Unlike MiTMAB and OcTMAB, which block dynamin recruitment to the 
membranes, dynole-34-2, dyngo-4a and dynasore block dynamin function after its 
recruitment [30]. MiTMAB, OcTMAB also bind to the PH-domain of the dynamin 
molecule, unlike the other inhibitors, which bind to the G domain. An obvious reason 
for the prevention of migration after the use of dynamin inhibitors is the potential 
importance of internalisation for receptor activation and ultimately signal transduction. 
We, therefore, employed a different clathrin-coated pits endocytosis inhibitor, pitstop 
2 and its negative control compound to analyse whether internalisation is a pre-
requisite for migration. In both THP-1 cells and Jurkat cells pitstop 2 did not prevent 
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CCL3- and CXCL12-induced migration, respectively, which is evidence that receptor 
internalisation is not necessary to activate cell migration as had been described 
already for the CCR2b receptor [37].  
In our study we detect distinct differences between the CC- and CXC-receptors. 
Traditionally it has been shown that CXCR4 activation leads to chemotaxis in a β-
arrestin 2, ERK 1/2, Gβγ dependent manner and is PI3K dependent [38, 39]. 
Therefore the implication of the dynamin PH domain in cell migration for CXCL12 is 
in line with the already published signalling networks, whereas the PH domain is not 
necessary for CCL3-induced migration, since this migration is independent of PI3K 
activation [15]. Overall our study showed that there are distinct differences in 
signalling networks used by CC-receptors compared to CXC-receptors which will 
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target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and 




Figures and legends 
 
Figure 1: Cell migration towards CCL3 but not towards CXCL11 or CXCL12 is 
blocked by dynasore. a) THP-1 cells were treated with 16, 40 or 80 µM of dynasore. 
b) THP-1 cells were treated with 40 µM of dynasore. Migration was induced with 1 
nM CXCL12. c) Activated T-lymphocytes were treated with 80 µM of dynasore and 
migration was induced with 20 nM CCL3. d) Activated T-lymphocytes were treated 
with 80 µM of dynasore and migration was induced with 1 nM CXCL11. e) Jurkat 
cells were treated with 80 µM of dynasore and migration was induced with 1 nM 
CXCL12. Base level of migration was determined in the absence of chemokines. 
Statistical analysis were performed using a one-way ANOVA with a Bonferroni 
Multiple comparison test as post-test ** showing a p value <0.01 and *** <0.001. 
Data represent the mean ± S.E.M. of at least three independent experiments. 
 
Figure 2: Cell migration towards CCL3, CXCL11 and CXCL12 is blocked by dyngo-
4a. a) THP-1 cells were treated with 80 µM of dyngo-4a. Migration was induced with 
1 nM CCL3. b) Activated T-lymphocytes were treated with 80 µM of dyngo-4a and 
migration was induced with 20 nM CXCL11. c) THP-1 cells were treated with 80 µM 
of dyngo-4a and migration was induced with 1 nM CXCL12. d) Jurkat cells were 
treated with 80 µM of dyngo-4a and migration was induced with 1 nM CXCL12. 
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Statistical analysis were performed using a one-way ANOVA with a Bonferroni 
Multiple comparison test as post-test with * showing a p value <0.05, ** showing a p 
value <0.01 and *** showing a p value < 0.001. Data represent the mean ± S.E.M. of 
at least three independent experiments. 
 
Figure 3: Effect of different dynamin inhibitors on migration towards CCL3 and 
CXCL12. a) THP-1 cells were treated with 1 µM of iminodyn-17 and 1 µM of 
iminodyn-22. Migration was induced with 1 nM CCL3. b) Jurkat cells were treated 
with 1 µM of iminodyn-17 and 1 µM of iminodyn-22. Migration was induced with 1 nM 
CXCL12. c) THP-1 cells were treated with 15 µM dynole-31-2 and 15 µM dynole-34-
2 and migration was induced with 1 nM CCL3 d) Jurkat cells were treated with 15 µM 
dynole-31-2 and 15 µM dynole-34-2 and  migration was induced with 1 nM CXCL12. 
e) THP-1 cells were treated with 10 µM of MiTMAB and migration was induced with 1 
nM CCL3. f) Jurkat cells were treated with 10 µM of MiTMAB and 5 µM of OcTMAB. 
Migration was induced with 1 nM CXCL12. g) THP-1 cells were treated with 5 µM of 
OcTMAB. Migration was induced with 1 nM CCL3. h) THP-1 cells were treated with 
10 µM of MiTMAB and 5 µM of OcTMAB. Migration was induced with 1 nM CXCL12. 
Statistical analysis were performed using a one-way ANOVA with a Bonferroni 
Multiple comparison test as post-test with *** showing a p value < 0.001. Data 
represent the mean ± S.E.M. of at least three independent experiments. 
 
Figure 4: Effect of endocytosis inhibitors on migration towards CCL3 and CXCL12. a) 
THP-1 cells were treated with 10 µM of pyrimidyn-7. Migration was induced with 1 
nM CCL3. b) THP-1 cells were treated with 10 µM of pyrimidyn-7. Migration was 
induced with 1 nM CXCL12 and migrated cells were counted after 4 hours. c) THP-1 
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cells were treated with 1.25 µM of pitstop 2 and pitstop 2 negative control compound 
and 30 µM of pitstop 2 and pitstop 2 negative control compound, respectively. 
Migration was induced with 1 nM CCL3. d) Jurkat cells were treated with 30 µM of 
pitstop 2 and pitstop 2 negative control compound, respectively and migration was 
induced with 1 nM CXCL12. Statistical analysis were performed using a one-way 
ANOVA with a Bonferroni Multiple comparison test as post-test with ** showing a p 
value < 0.01 and *** showing a p value < 0.001. Data represent the mean ± S.E.M. 
of at least three independent experiments. 
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Table 1: Overview of dynamin inhibitors 
Inhibitor Mode of action IC 50(SVE) a (µM) Specificity Dynamin 
I versus II (µM) 
Refs 
Dyngo-4aTM G domain: allosteric site 16±1.2 Dynamin I selective 
0.38±0.05 vs 2.6±0.12 
[30, 
35] 
Dynasore Unknown: non-competitive 
inhibition 
79.3±1.3 Non-selective [35] 
Dynole-34-2TM G domain: uncompetitive with 
GTP 
105 Non-selective [36] 
Iminodyn 22TM G domain: uncompetitive with 
GTP 
99.5±1.7 Non-selective [33] 
Pyrimidin-7TM Competitively inhibits both GTP 
and phospholipid binding 
Not reported Non-selective 
1.1vs1.8 
[32] 
MiTMAB TM PH domain: competitive with lipid 
and non-competitive with GTP 
105 Non-selective [36] 
OcTMAB TM PH domain: competitive with lipid 
and non-competitive with GTP 
Not reported Non-selective [36] 
a FM4-64 uptake in synaptosomes 
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